

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for isolating a polynucleotide encoding an antibody against a lesional tissue, wherein the method comprises the steps of:
 - (a) isolating a single lesional tissue-infiltrating B cell from a lesional tissue; and
 - (b) obtaining a polynucleotide encoding an antibody heavy chain and a polynucleotide encoding an antibody light chain of from the isolated B cell.
2. (Original) The method of claim 1, wherein the lesional tissue is a cancer tissue.
3. (Original) The method of claim 1, wherein step (a) of isolating a lesional tissue-infiltrating B cell comprises the step of excising a region comprising a B cell from a section of said lesional tissue.
4. (Currently amended) The method of claim 1, wherein step (b) ~~of obtaining a polynucleotide encoding an antibody~~ comprises the step of amplifying a gene encoding an antibody variable region.
- 5-8. (Canceled)
9. (Currently amended) A method for producing an antibody, wherein the method comprises the steps of:
 - (a) isolating a single lesional tissue-infiltrating B cell from a lesional tissue;

(b) obtaining a polynucleotide encoding an antibody heavy chain and a polynucleotide encoding an antibody light chain of the isolated B cell;

(c) preparing one or more expression vectors comprising the polynucleotides;

(d) transforming a host cell with the one or more expression vectors to obtain a transformed host cell expressing the polynucleotides;

(e) culturing the transformed host cell of claim 8; and

(f) recovering an antibody expressed by the transformed host cell which is the expression product.

10-11. (Canceled)

12. (Currently amended) The antibody production method of claim 9, wherein the method further comprises the steps of:

- (1) contacting the antibody obtained by the method of claim 9 with a lesional tissue;
- (2) detecting ~~the~~ binding between the antibody and the lesional tissue; and
- (3) selecting the [[an]] antibody if it [[that]] binds to the lesional tissue.

13. (Canceled)

14. (New) The method of claim 1, wherein the step of isolating a lesional tissue-infiltrating B cell comprises excising a region comprising the B cell from a section of the lesional tissue by laser microdissection (LMD).

15. (New) The method of claim 1, wherein the method is repeated for twenty or fewer B cells.

16. (New) The method of claim 1, wherein the method is repeated for five or fewer B cells.

17. (New) The method of claim 1, wherein the lesional tissue is removed from a patient by surgical excision.
18. (New) The method of claim 3, wherein the lesional tissue is frozen.
19. (New) The method of claim 3, wherein the lesional tissue is fixed.
20. (New) The method of claim 1, wherein the B cell is a human B cell.
21. (New) The method of claim 1, further comprising obtaining the sequence of a variable region of the antibody heavy chain or light chain.
22. (New) The method of claim 1, wherein the lesional tissue is an atherosclerotic lesion.
23. (New) The method of claim 1, wherein the lesional tissue is an inflammatory disease lesion.
24. (New) The method of claim 1, wherein the lesional tissue is a lesion generated by an infectious pathogen.
25. (New) The method of claim 1, wherein the lesional tissue is an autoimmune disease lesion.
26. (New) The method of claim 1, wherein the lesional tissue is an artificially prepared lesion.